Barclays
ARTV

Barclays’s Artiva Biotherapeutics ARTV Stock Holding History

Barclays’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4K Buy
+3,336
New +$30.4K ﹤0.01% 4465
2025
Q4 		– Sell
-12,696
Closed -$36.4K – 5789
2025
Q3 		$36.4K Buy
12,696
+10,790
+566% +$28.9K ﹤0.01% 4845
2025
Q2 		$2.88K Sell
1,906
-20,847
-92% -$43.8K ﹤0.01% 5013
2025
Q1 		$68.3K Sell
22,753
-1,408
-6% -$7.6K ﹤0.01% 4526
2024
Q4 		$244K Buy
24,161
+4,545
+23% +$54.6K ﹤0.01% 4216
2024
Q3 		$303K Buy
+19,616
New +$227K ﹤0.01% 4084

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Barclays's ARTV Position: Q2 2026 in Review

Barclays opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 3,336 shares worth $32.4K. The stake represents ﹤0.01% of the portfolio and ranks #4465 among its holdings. This is a return to the name: Barclays previously reported a position in ARTV as recently as Q3 2025.

Barclays first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $303K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Barclays held 3,336 shares of Artiva Biotherapeutics worth $32.4K as of Q2 2026.
  • Artiva Biotherapeutics was a new Barclays position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4465 holding.
  • Barclays first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
  • Barclays's Artiva Biotherapeutics position peaked at $303K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.